sosjtb,
The question is, what is Humanigen's most valuable asset? I think, for the very near term, it is having a float of 229M shares, which is 110M more shares in the market, than the company has issued. These shares are controlled by Dale's entities, which I view as our financing arm, and as we know, these shares are currently virtually worthless.
But the Asset Purchase Agreement, versus a Buy-Out, does not represent Durrant abandoning those shares, which have been loaned out. They are significantly beneficially owned by Humanigen. I think Humanigen owns 110M of those shares. So it may be that the recall of the loaned shares may be announced by Dale, if not Durrant.
Once, or as, the loaned shares have been recalled, I think we could announce a stock-for-stock merger or business consolidation with Novavax. That will then become our most valuable asset, as it could result in billions of annual revenue dollars, assuming that lenz was integrated into the Novavax prototype vaccine.
I feel like you're calling cadence, and have just ordered the first row of troops to execute a "to the rear, march" command. I certainly feel that positing what I have just sequenced is a dramatic change in course.
News 
Market Data 
Discover 
